Acquisition between Durect and Bausch Health advances liver disease treatment.
3 reports, 3 independent
Updated Aug 9
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Acquisition between Durect and Bausch Health advances liver disease treatment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Durect (United States)
company in Cupertino, United States
Nothing else this week.
-
Bausch Health
multinational specialty drugs company based in Laval, Quebec, Canada
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyBausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment Bausch Health Companies Inc. (NYSE:BHC) is one of the most undervalued Canadian stocks to buy now. On July
- Simply Wall St.3 Promising Penny Stocks With Market Caps Over $10M As the U.S. stock market navigates a landscape marked by anticipation of Federal Reserve interest rate decisions and major tech earnings, investors
- PR NewswireBausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease DURECT's lead asset, Larsucosterol, is an epigenetic modulator